BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2512-2556.e9. [PMID: 34051985 DOI: 10.1053/j.gastro.2021.04.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillèmoz M, Michetti P. Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100104] [Reference Citation Analysis]
2 Meserve J, Singh S. Editorial: risk of pneumonia in IBD-reading between the lines! Aliment Pharmacol Ther 2021;54:1490-1. [PMID: 34741329 DOI: 10.1111/apt.16655] [Reference Citation Analysis]
3 Ho EY, Singh S, Terdiman JP. Providing the Best Care for Patients With Crohn's Disease: An Examination of the New AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2557-62. [PMID: 34051986 DOI: 10.1053/j.gastro.2021.04.024] [Reference Citation Analysis]
4 Hong SJ, Zenger C, Pecoriello J, Pang A, Vallely M, Hudesman DP, Chang S, Axelrad JE. Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. Inflamm Bowel Dis 2022:izac035. [PMID: 35262671 DOI: 10.1093/ibd/izac035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
6 Ahuja D, Singh S. Comparative efficacy trials in inflammatory bowel disease: current and future implications for practice. Curr Opin Gastroenterol 2022;38:337-46. [PMID: 35762693 DOI: 10.1097/MOG.0000000000000854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rakowsky S, Papamichael K, Cheifetz AS. Choosing the right biologic for complications of inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2036122] [Reference Citation Analysis]
8 Tsai L, McCurdy JD, Ma C, Jairath V, Singh S. Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts. Inflamm Bowel Dis 2021:izab287. [PMID: 34792604 DOI: 10.1093/ibd/izab287] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chugh R, Gaidos JK. Fertility and Pregnancy in Crohn's Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.012] [Reference Citation Analysis]
10 Kim M, Jeon J. Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases. IJMS 2022;23:2846. [DOI: 10.3390/ijms23052846] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Yzet C, Brazier F, Sabbagh C, Fumery M. Managing complex perianal disease after anti-TNF failure: Where to go next? Current Research in Pharmacology and Drug Discovery 2022;3:100081. [DOI: 10.1016/j.crphar.2022.100081] [Reference Citation Analysis]
12 Greer MC, Taylor SA. Perianal Imaging in Crohn Disease: Current Status With a Focus on MRI, From the AJR Special Series on Imaging of Inflammation. AJR Am J Roentgenol 2021. [PMID: 34549607 DOI: 10.2214/AJR.21.26615] [Reference Citation Analysis]
13 Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2496-508. [PMID: 34051983 DOI: 10.1053/j.gastro.2021.04.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2021;6:1002-14. [PMID: 34688373 DOI: 10.1016/S2468-1253(21)00312-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
15 D'Amico F, Peyrin-Biroulet L, Danese S. Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm. J Crohns Colitis 2022;16:ii30-41. [PMID: 35553665 DOI: 10.1093/ecco-jcc/jjac011] [Reference Citation Analysis]
16 Gubatan J, Frost S, Levitte S, Keyashian K. Rates and Predictors of Long-term Clinical Outcomes in Patients With Perianal Crohn's Disease on Biologic Therapy. J Clin Gastroenterol 2022. [PMID: 35703262 DOI: 10.1097/MCG.0000000000001729] [Reference Citation Analysis]